Treatment
Articles in this section
-
Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
This Training Manual was designed and updated in February 2018 by Treatment Action Group (TAG), an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.
The purpose (...) More -
Genotypes Fact Sheet
A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat and cure HCV.
HCV has six genotypes, labeled 1 through 6. There are also (...) More -
Viekira XR and Technivie Fact Sheet
Viekira XR is a combination of hepatitis C virus–fighting drugs (paritaprevir/ritonavir/ombitasvir and dasabuvir) that block different steps of the virus life cycle. In the United States, Viekira XR is approved for people with hepatitis C genotype 1 who are over 18 years old. Viekira XR was (...) More
-
Epclusa Fact Sheet
Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older. The fact sheet provides information about this treatment (...) More
-
The HepC Pill Bill An insight into the availability, pricing and accessibility of HCV treatment
Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a course of pegylated interferon injections and ribavirin tablets, which all in all were expensive, toxic, and needed 24 to 28 weeks to (...) More